Trials / Completed
CompletedNCT03318809
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 986 | tablets for oral administration |
Timeline
- Start date
- 2017-12-12
- Primary completion
- 2018-03-12
- Completion
- 2018-04-05
- First posted
- 2017-10-24
- Last updated
- 2022-06-23
- Results posted
- 2021-01-27
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03318809. Inclusion in this directory is not an endorsement.